Clinical Trials Browser

Phase 1 × Terminated × Neoplasm, Residual × Clear all

NCT01751425 2025-06-03

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Phase 1 Terminated

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT03038230 2025-04-06

MCLA-117 in Acute Myelogenous Leukemia

Phase 1 Terminated

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT01743807 2025-01-27

Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia

Phase 1 Terminated

4 enrolled 6 charts

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04310592 2024-12-12

CYNK001AML01

Phase 1 Terminated

Other hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT05601830 2024-11-06

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Phase 1 Terminated

Neoplasm, Residual

NCT04748848 2023-03-02

A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

Phase 1 Terminated

Other hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasm, Residual